Neuberger Berman Group
ATOS icon

Neuberger Berman Group’s Atossa Therapeutics ATOS Stock Holding History

Neuberger Berman Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-980
Closed -$12.2K – 2042
2025
Q2 		$12.2K Hold
980
– – ﹤0.01% 2038
2025
Q1 		$9.89K Buy
980
+161
+20% +$1.96K ﹤0.01% 1964
2024
Q4 		$11.6K Hold
819
– – ﹤0.01% 1918
2024
Q3 		$18.7K Buy
+819
New +$16.5K ﹤0.01% 1902

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Neuberger Berman Group's ATOS Position: Q3 2025 in Review

Neuberger Berman Group sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 980 shares — an estimated $12.2K sold.

Neuberger Berman Group first reported a position in ATOS in Q3 2024 and held it in 4 quarters. The position peaked at $18.7K in Q3 2024. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Neuberger Berman Group reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 980 Atossa Therapeutics shares in Q3 2025, an estimated $12.2K.
  • Neuberger Berman Group first reported a position in Atossa Therapeutics in Q3 2024 and held it in 4 quarters.
  • Neuberger Berman Group's Atossa Therapeutics position peaked at $18.7K in Q3 2024.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Neuberger Berman Group's 13F filing for Q3 2025, filed 12 Nov 2025.